Literature DB >> 12379634

Pharmacovigilance: towards a better understanding of the benefit to risk ratio.

L S Simon1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12379634      PMCID： PMC1766711          DOI： 10.1136/ard.61.suppl_2.ii88

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  Overview of different logistical approaches to postmarketing surveillance.

Authors:  B L Strom
Journal:  J Rheumatol Suppl       Date:  1988-10

2.  Postmarketing studies of drug efficacy.

Authors:  B L Strom; K L Melmon; O S Miettinen
Journal:  Arch Intern Med       Date:  1985-10

Review 3.  Postmarketing surveillance methodologies.

Authors:  S A Edlavitch
Journal:  Drug Intell Clin Pharm       Date:  1988-01

Review 4.  Why do doctors not report adverse drug reactions?

Authors:  J M Leiper; D H Lawson
Journal:  Neth J Med       Date:  1985       Impact factor: 1.422

5.  The epidemiological evaluation of drugs.

Authors:  S Shapiro
Journal:  Acta Med Scand Suppl       Date:  1984

6.  Spontaneous adverse drug reaction reporting vs event monitoring: a comparison.

Authors:  A P Fletcher
Journal:  J R Soc Med       Date:  1991-06       Impact factor: 18.000
  6 in total
  2 in total

Review 1.  Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence.

Authors:  Alexis Ogdie; J M Gelfand
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

2.  Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.

Authors:  Min Wu; Qingxiong Yu; Qingfeng Li
Journal:  Oncotarget       Date:  2016-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.